<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134461">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01878279</url>
  </required_header>
  <id_info>
    <org_study_id>21397</org_study_id>
    <nct_id>NCT01878279</nct_id>
  </id_info>
  <brief_title>HSV Oral Reactivation in Children</brief_title>
  <official_title>Longitudinal Study to Evaluate the Frequency of HSV-1 Oral Reactivation in Children in Dar es Salaam, Tanzania</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the proposed study, the investigators will carry out novel research to evaluate both
      symptomatic and asymptomatic daily oral herpes simplex virus (HSV) shedding rates and copy
      number in children with and without HIV.

      Study Objectives:

        1. To evaluate the frequency of oral HSV reactivation in HIV-infected and uninfected
           children

           Secondary Objectives:

        2. To determine the acceptability of performing daily oral swabs in children age 3-12
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>HSV detection rate</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>HSV copy number</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>compliance with daily swabs</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>HSV-1</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>HIV negative</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV positive</arm_group_label>
    <description>HIV positive children in care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Underlying medical illness</intervention_name>
    <arm_group_label>HIV positive</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        For this Pilot study, we will enroll 20 HIV-infected and 10 HIV-uninfected children
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 3 and ≤12 years old

          -  parental/guardian consent and children's assent must be obtained and participants and
             parent/guardian must be able to comply with study procedures

          -  For HIV-infected group:  Positive HIV serology by either ELISA x 2, ELISA + WB or PCR
             testing

        Exclusion Criteria:

          -  age &lt;3 and &gt; 12 years old

          -  Acute illness which by opinion of the investigator makes enrollment in the trial
             unfeasible (including active tuberculosis, malaria or other opportunistic infection
             requiring treatment)

          -  co-enrollment in other therapeutic/intervention trials (observational trial
             enrollment is permitted).

          -  Stable co-administration of other medications is permitted (e.g. bactrim)

          -  For HIV-infected children; receiving or eligible for antiretroviral (ART) therapy by
             local standards
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Zuckerman, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MUHAS</name>
      <address>
        <city>Dar es Salaam</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <reference>
    <citation>Kasubi MJ, Nilsen A, Marsden HS, Bergström T, Langeland N, Haarr L. Prevalence of antibodies against herpes simplex virus types 1 and 2 in children and young people in an urban region in Tanzania. J Clin Microbiol. 2006 Aug;44(8):2801-7.</citation>
    <PMID>16891495</PMID>
  </reference>
  <reference>
    <citation>Grando LJ, Machado DC, Spitzer S, Nachman S, Ferguson F, Berentsen B, Yurgel LS. Viral coinfection in the oral cavity of HIV-infected children: relation among HIV viral load, CD4+ T lymphocyte count and detection of EBV, CMV and HSV. Braz Oral Res. 2005 Jul-Sep;19(3):228-34. Epub 2005 Nov 21.</citation>
    <PMID>16308613</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 12, 2013</lastchanged_date>
  <firstreceived_date>June 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
